Nivolumab for Relapsed or Residual Haematological Malignancies After

Clinical Trial Summary

This is a prospective study of the safety and efficacy of nivolumab for the treatment of relapsed or residual haematological malignancies after allogeneic stem cell transplantation (alloSCT). Eligible patients will receive nivolumab at a dose of 3mg/kg intravenously every 2 weeks. The primary objective is to evaluate the incidence, severity and treatment responsiveness of GVHD following nivolumab treatment post-alloSCT.

See also
Status	Clinical Trial	Phase
Terminated	`NCT03978312` - Nutrition Health Literacy of Cancer Patients and Their Support Networks.
Recruiting	`NCT03750994` - Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
Recruiting	`NCT04397705` - Remote Monitoring of Cancer Patients With Suspected Covid-19	Phase 1
Recruiting	`NCT05678621` - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension	Phase 2/Phase 3
Recruiting	`NCT05203809` - Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
Recruiting	`NCT05298930` - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation	N/A
Not yet recruiting	`NCT06395220` - Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
Recruiting	`NCT05786716` - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations	Phase 2/Phase 3
Not yet recruiting	`NCT04673305` - Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies	N/A
Recruiting	`NCT05722886` - DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol	Phase 2/Phase 3
Recruiting	`NCT05768178` - DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.	Phase 2/Phase 3
Completed	`NCT03855969` - Central Venous Access Device Removal in Cancer Patients
Recruiting	`NCT04174053` - Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units	N/A
Recruiting	`NCT05770544` - DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.	Phase 2/Phase 3
Recruiting	`NCT05379738` - Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy	N/A
Completed	`NCT04236063` - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Recruiting	`NCT05695638` - Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Recruiting	`NCT04298892` - Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
Withdrawn	`NCT03688789` - Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology	N/A
Withdrawn	`NCT04331483` - A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts	N/A

NCT number	NCT03146468
Study type	Interventional
Source	Melbourne Health
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 8, 2017
Completion date	March 1, 2022

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation — NIVALLO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms